Sup. Fig. 1. Addition of dox/TMP and/or stabilization of DHFR fusion proteins has no adverse effect on a number of cell readouts. ARPE-19 cells were plated and maintained in culture for 1 week, during which serum was gradually removed. After 1 week, serum was eliminated and cells were maintained for an additional week prior to addition of DMSO or dox/TMP for 48 h. Administration of dox/TMP or stabilization of DHFR-IkBα has no detrimental effect on cell viability (resazurin assay, A), pyropoptosis (LDH release, B), ATP content of the cell (Cell Titer Glo 2.0, C), or TEER (D, E). n ≥ 3 independent experiments for all panels. Mean ± S.D. for panels A-C, mean ± S.E.M. for panels D, E.

Sup. Fig. 2. A2E and 4-HNE do not cause an increase in NFκB reporter activity. (A) Zoomed in version of Fig. 5C to show basal IL-6 protein levels. n = 3, * p < 0.05, unpaired, one-tailed t-test assuming equal variance. (B) Stable ARPE-19 cells expressing 5NF-GLuc were treated with the indicated amounts of A2E or 4-HNE for 24 h followed by a GLuc assay, n = 4. (C, D) IL-6 transcript levels after indicated treatment for 24 h. Mean ± S.D. for all bar graphs in this figure.